In re application of:

Evan C. Unger et al.

Serial No.: 09/218,660

Group Art Unit: 1616

Filed: December 22, 1998

Examiner: S. Sharareh

For: NOVEL METHODS TARGETED COMPOSITIONS

FOR DIAGNOSTIC AND THERAPEUTIC USE

I, S. Maurice Valla, Registration No. 43,966, certify that this correspondence is being deposited with the U.S.—Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On April 12, 2000

S. Maurice Valla, Registration No. 43,966

BOX SEQUENCE

Assistant Commissioner for Patents Washington, D.C. 20231

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the	
contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.	
I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.	
I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.	
I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.	

Ц	I hereby state that the substitute copy of the coaccordance with 37 CFR §1.825(b), is the san	• ,	
	I hereby state that the substitute copy of the computer readable form, submitted accordance with 37 CFR §1.825(d), contains identical data to that originally file		
Date:	S. Mau	Africe / And rice Valla ration No. 43,966	

Woodcock Washburn Kurtz Mackiewicz & Norris LLP One Liberty Place - 46th Floor

Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

C 1997 WWKMN